Replimune Group, Inc. - Common Stock (NQ:REPL)

13.40 +0.16 (+1.21%)

Delayed Quote Updated: 1:18 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

What's Going On With Cancer-Focused Replimune Stock Today? ↗

December 05, 2023

Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 05, 2023

Via Benzinga

8 Health Care Stocks Whale Activity In Today's Session ↗

November 07, 2023

Via Benzinga

The Latest Analyst Ratings for Replimune Group ↗

August 01, 2023

Via Benzinga

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

July 31, 2023

From Incyte

Via Business Wire

Analyst Ratings for Replimune Group ↗

June 07, 2023

Via Benzinga

Replimune Group Inc. (NASDAQ: REPL) Making Surprising Moves in Monday Session

June 05, 2023

Via Investor Brand Network

Recap: Replimune Group Q4 Earnings ↗

May 18, 2023

Via Benzinga

Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review ↗

June 09, 2023

The Nasdaq held near 52-week highs while small caps ramped up.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 05, 2023

Via Benzinga

ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes ↗

June 05, 2023

ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference.

Via Investor's Business Daily

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗

April 13, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform ↗

December 12, 2022

Last Thursday, Replimune Group Inc (NASDAQ: REPL) announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical.

Via Benzinga

Analyst Ratings for Replimune Group ↗

December 07, 2022

Via Benzinga

Replimune Group: Q2 Earnings Insights ↗

November 03, 2022

Replimune Group (NASDAQ:REPL) reported its Q2 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Analyst Ratings for Replimune Group ↗

May 24, 2022

Analysts have provided the following ratings for Replimune Group (NASDAQ:REPL) within the last quarter:

Via Benzinga

Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 05, 2023

Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.

Via Benzinga

PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday ↗

December 12, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session ↗

December 07, 2022

Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 07, 2022

Via Benzinga

Replimune Shares Surge After Early Data From Pretreated Melanoma Patients ↗

December 07, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 07, 2022

Via Benzinga

Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts ↗

October 14, 2022

Via Benzinga

Wells Fargo To Surge Around 20%? Here Are 5 Other Price Target Changes For Monday ↗

October 03, 2022

Goldman Sachs raised Wells Fargo & Company (NYSE: WFC) price target from $46 to $48. Goldman Sachs analyst Richard Ramsden upgraded the stock from Neutral to Buy. Wells Fargo shares rose 1.1% to $40.68...

Via Benzinga

PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst ↗

May 25, 2022

Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than...

Via Benzinga

Replimune Group: Q4 Earnings Insights ↗

May 19, 2022

Replimune Group (NASDAQ:REPL) reported its Q4 earnings results on Thursday, May 19, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Replimune Group missed...

Via Benzinga

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗

March 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 18, 2022

On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.